✦ The FDA’s Oncologic Drugs Advisory Committee voted to keep most indications for a handful of immune checkpoint inhibitors that target programmed death-1/programmed death ligand-1 (PD-1/PD-L1) and received accelerated approval pending further clinical trial data (RSP 4/21, p. 1). Receiving “yes” votes were Tecentriq (atezolizumab) from Roche subsidiary Genentech USA, Inc. for certain triple-negative breast cancers and urothelial carcinomas and Merck & Co., Inc.’s Keytruda (pembrolizumab) for certain urothelial carcinomas and hepatocellular carcinomas. Keytruda received a negative vote for certain gastric cancers and Bristol Myers Squibb’s Opdivo (nivolumab) did also for certain hepatocellular carcinomas. View the meeting materials at https://bit.ly/3uj4XqJ.
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.